INmune Bio, Inc. (INMB) Tops Q2 EPS by 13c

INmune Bio, Inc. (NASDAQ: INMB) reported Q2 EPS of ($0.50), $0.13 better than the analyst estimate of ($0.63).

For earnings history and earnings-related data on INmune Bio, Inc. (INMB) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Nuvectis Pharma (NVCT) PT Raised to $39 at H.C. Wainwright
• e-STORAGE and Axpo to deploy 8 MW battery system in southern Italy